|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (2002)) |
IUPAC Name ![]() |
| (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 7712 | fulvestrant |
Synonyms ![]() |
| Faslodex® |
| ICI 182,780 |
| ICI 182780 |
| ICI182780 |
| ZD-9238 |
Database Links ![]() |
|
| BindingDB Ligand | 50169743 |
| CAS Registry No. | 129453-61-8 |
| ChEBI | CHEBI:31638 |
| ChEMBL Ligand | CHEMBL1358 |
| DrugBank Ligand | DB00947 |
| NURSA Ligand | 10.1621/WZYNUBUNGT |
| PharmGKB Drug | PA164747170 |
| PubChem CID | 104741 |
| Search Google for chemical match using the InChIKey | VWUXBMIQPBEWFH-WCCTWKNTSA-N |
| Search Google for chemicals with the same backbone | VWUXBMIQPBEWFH |
| Search PubMed clinical trials | fulvestrant |
| Search PubMed titles | fulvestrant |
| Search PubMed titles/abstracts | fulvestrant |
| Wikipedia | Fulvestrant |
| Comments |
| Fulvestrant is an estrogen receptor antagonist. |